WEDNESDAY 23 MARCH - EDUCATION SESSION

Educational Session for PhD Students, MD Students and MD PhD Students

Venue: Herrenhausen Palace

09:00-10:40

Education Session 1

Chairs: Toni Cathomen, Axel Schambach, Hildegard Büning

09:00-09:10  Toni Cathomen, President DG-GT - University of Freiburg, Axel Schambach, President Elect DG-GT - Hannover Medical School; Hildegard Büning, Scientific Secretary DG-GT - Hannover Medical School 

Welcome address


09:10-09:40  Hildegard Büning, Hannover Medical School  

Optimizing delivery tools for gene therapy (AAV/LV/Nonviral) 


09:40-10:10  Axel Schambach, Hannover Medical School  

Exploiting stem cells for combined gene and cell therapies 


10:10-10:40  Toni Cathomen, University of Freiburg  

Designer nucleases: Basics, challenges and beyond

10:40-11:00

Break

11:00-12:00

Education Session 2

Chairs: Toni Cathomen, Axel Schambach, Hildegard Büning

11:00-11:30  Frank Buchholz, Universiy of Dresden 

Evolving molecular scissors for antiviral gene therapy


11:30-12:00  Boris Fehse, University of Hamburg  

Translating HIV gene therapy from the lab to the clinic

 

WEDNESDAY 23 MARCH

Venue: Herrenhausen Palace

12:00-13:30

Avro_Programme.png

Registration

13:30-14:00

Avro_Programme.png

Opening Ceremony

Toni Cathomen, University of Freiburg & President DG-GT; Axel Schambach, Hannover Medical School & President-elect DG-GT; Hildegard Büning, Hannover Medical School & Scientific Secretrary DG-GT; Michael Manns, President of Hannover Medical School; Selahattin Danisman, Program Director, Volkswagen Foundation

14:00-16:15

Avro_Programme.png

Session 1: Optimizing the vector world and modeling systems – Part A

Chairs: Hildegard Büning, Hannover Medical School; Axel Schambach, Hannover Medical School

14:00-14:15  Hildegard Büning, Hannover Medical School; Axel Schambach, Hannover Medical School

Optimizing the vector world – current status in a nutshell


14:15-14:45  Els Verhoeyen, University of Nice, ENS Lyon  

INV01:  Novel lentiviral pseudotypes for T and NK cell gene therapy and ‘nanoblades’ for efficient gene editing in hematopoietic gene therapy target cells. 


14:45-15:15  Leszek Lisowski, University of Sydney

INV02:  Canonical AAV gene therapy and clinical gene editing: capsid evolution and translational vectorology 


15:15-15:45  Joel Rurik, University of Pennsylvania  

INV03:  CAR T cells produced in vivo to treat cardiac injury


15:45-16:00  Rajendra Khanal, Hannover Medical School

OR01:  mRNA-based therapies for liver diseases: HNF4A mRNA administration via lipid nanoparticles miti

gates liver fibrosis in preclinical models


16:00-16:15  Zoltan Ivics, Paul Ehrlich Institute, Langen

OR02: Engineered Sleeping Beauty transposase redirects transposon integration away from genes

16:15-16:45

Avro_Programme.png

Break

16:45-19:15

Avro_Programme.png

Session 2: Optimizing the vector world and modeling systems – Part B

Chairs: Christian Kupatt, Technische Universität München; Michael Ott, Hannover Medical School

16:45-17:00  Christian Kupatt, Technische Universität München, Michael Ott, Hannover Medical School

Optimizing genetic payload and modeling systems – current status in a nutshell


17:00-17:45  Luigi Naldini, SR Tiget, Milan  

INV04:  Hematopoietic stem cell gene therapy: how to choose the best tools and broaden its therapeutic scope


17:45-18:15  Alberto Auricchio, Tigem Naples  

INV05:  Expanding AAV transfer capacity on the retina 


18:15-18:45  Cornelia Lee-Thedieck, Leibniz University Hannover  

INV06:  In vitro models of the hematopoietic stem cell niche: from fundamental research to application as test systems 


18:45-19:00  Reto Eggenschwiler, Hannover Medical School

OR03: PB-PE, a piggyBac prime editing platform for efficient evaluation of optimal CRISPR-PE designs


19:00-19:15  Dawid Glow, University Medical Center Hamburg-Eppendorf

OR04: CRISPR-to-Kill (C2K) - development of a versatile method that utilizes the bacterial immune system to kill cancer cells

19:15 -19:30

Avro_Programme.png

Break

19:30-20:15

Avro_Programme.png

Keynote 1: Wolfram Ostertag Lecture

Chair: Christopher Baum, Charité, Berlin Institute of Health ; Carol Stocking, University Medical Center Hamburg - Eppendorf


19:30-20:15  Rudolf Jaenisch, Whitehead Institute, MIT, Boston

INV07:  Genomic integration of SARS-CoV-2 sequences and potential relevance for COVID-19

20:15

Avro_Programme.png

Dinner Reception

 

THURSDAY 24 MARCH

08:00-09:00

Registration

09:00-11:15

Session 3: iPSC- and stem cell-based cell therapies

Chairs: Thomas Moritz, Hannover Medical School; Tobias Cantz, Hannover Medical School

09:00-09:15  Thomas Moritz, Hannover Medical School; Tobias Cantz, Hannover Medical School

iPSC and stem cell-based therapies – current status in a nutshell


09:15-09:45  Ulrich Martin, Hannover Medical School  

INV08:  hiPS cells for clinical heart repair: Generation of GMP-compliant cell lines, large scale cardiomyocyte production and preclinical evaluation in a non-human primate model


09:45-10:15  Miguel Esteban, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences

INV09:  Single stem cells


10:15-10:45  Claire Booth, University College London  

INV10:  Stem cell gene therapy for immune deficiencies; new approaches to correction


10:45-11:00  Daniela Paasch, Hannover Medical School

OR05: A universal platform to generate chimeric antigen receptor macrophages from human stem cell sources


11:00-11:15  Masako Monica Kaufmann, Medical Center – University of Freiburg

OR06: Universal CAST-Seq: Target sequence-independent detection of CRISPR-Cas off-target effects in primary human stem cells 

11:15-11:45

Break

11:45-13:00

Session 4: Manfred Schmidt Memorial Session

Chairs: Christof von Kalle, Charité, Berlin Institute of Health 

11:45-12:00  Christof von Kalle, Charité, Berlin Institute of Health

Introduction


12:00-12:30 Alain Fischer, Necker-Enfants Malades Hospital, Paris  

INV11:  Long term analysis of gene therapy for SCID and related diseases


12:30-13:00 David Williams, Harvard Medical School, Boston  

INV12:  Flipping the switch; post-transcriptional genetic silencing of BCL11A to treat Sickle Cell Disease

13:00-14:00

Lunch

14:00-16:00

Session 5: Evolving topics in gene and cell therapy, including zoonoses and infectious diseases

Chairs: Boris Fehse, University of Hamburg; Christine Falk, Hannover Medical School

14:00-14:15 Boris Fehse, University of Hamburg; Christine Falk, Hannover Medical School

Evolving topics in gene and cell therapy – current status in a nutshell


14:15-14:45 Stefan Pöhlmann, DPFZ, Göttingen  

INV13:  Coronavirus entry into cells


14:45-15:15  Axel Schambach, Hannover Medical School; Ulrich Kalinke, TWINCORE, Hannover

INV14:  Preventive strategies for current and future pandemics – a Hannover perspective


15:15-15:45  Hinrich Staecker, University of Kansas  

INV15:  Vectorization approaches for different human inner ear diseases: Regeneration, protection and treatment of genetic disorders 


15:45-16:00  Lea Krutzke, University of Ulm

OR07: Process-related impurities in the ChAdOx1 nCov-19 vaccine

16:00-16:30

Break

16:30-18:45

Session 6: Novel approaches in cancer therapy

Chairs: Dirk Nettelbeck, DKFZ, Heidelberg; Michael Morgan, Hannover Medical School

16:30 - 16:45  Dirk Nettelbeck,DKFZ, Heidelberg, Michael Morgan, Hannover Medical School

Novel approaches in cancer therapy – current status in a nutshell


16:45-17:15  Guy Ungerechts, NCT Heidelberg  

INV16:  Immunovirotherapy for Cancer


17:15-17:45  Benjamin Rengstl, BionNTech, Mainz  

INV17:  BNT211: A Phase I trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors


17:45-18:15  Martin Sauer, Hannover Medical School  

INV18:  Off the shelf cellular immunotherapy: Dream or Necessity?


18:15-18:30  Ulrike Naumann, University of Tübingen 

OR08: Immunogenic cell death determines the therapeutic impact of the oncolytic adenovirus XVir-N-31 in glioma and induces abscopal effects in combination with immune checkpoint inhibition


18:30-18:45  Maria Silvia Roman Azcona, Medical Center – University of Freiburg

OR09: Sustained modulation of immune checkpoint expression in CAR T cells upon transient exposure to a designer epigenome modifier

18:45-19:00

Break

19:00-19:45

Keynote 2: Making gene therapy a clinical reality

Chairs: Hinrich Abken, Regensburg Center for Interventional Immunology

19:00-19:45  Carl June, University of Pennsylvania  

INV19:  Updates with CAR T

 

FRIDAY 25 MARCH

08:30-09:00

Registration

09:00-11:15

Session 7: Genome and epigenome editing: On the road towards the clinic

Chairs: Claudio Mussolino, University of Freiburg; Julian Grünewald, Technische Universität München

09:00-09:15  Claudio Mussolino, University of Freiburg; Julian Grünewald, Technische Universität München

Genome and epigenome editing – current status in a nutshell


09:15-09:45  Toni Cathomen, University of Freiburg  

INV20:  On- and off-target effects of gene editing tools in human stem cells


09:45-10:15  Virgis Siksnys, Vilnius University  

INV21:  Novel CRISPR-Cas nucleases as potential genome editing tools?


10:15-10:45  Frank Buchholz, TU Dresden  

INV22:  Genome Editing with Designer-Recombinases 


10:45-11:00  Viviane Dettmer-Monaco, Medical Center- University of Freiburg

OR10: Gene editing of hematopoietic stem cells restores the cytotoxic T cell response in a murine model of familial hemophagocytic lymphohistiocytosis type 3


11:00-11:15  Adrian Schwarzer, Hannover Medical School

OR11: A four-color AAV6 system for efficient biallelic homology-directed genome editing (HDR) without AAV vector integration into CRISPR-Cas9 induced double-strand breaks

11:15-13:00

Poster Walk & Lunch

13:00-15:30

Session 8: Clinical translation of gene and cell therapies

Chairs: Stefan Kochanek, Uniklinik Ulm; Ulrike Köhl, Fraunhofer IZI, Leipzig

13:00-13:15  Stefan Kochanek, Uniklinik Ulm, Ulrike Köhl, Fraunhofer IZI, Leipzig

Clinical translation of gene and cell therapies – current status in a nutshell


13:15-13:45  Frank Staal, Leiden University  

INV23:  Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID


13:45-14:15  Thomas Thum, Hannover Medical School  

INV24:  (Pre)clinical development of noncoding RNA based therapeutics 


14:15-14:45  Fatima Bosch, Universitat Autònoma de Barcelona  

INV25:  Gene therapy for the Mature Onset Diabetes of the Young Type 3 (MODY3) 


14:45-15:00 Tobias Bexte, Goethe University Frankfurt

OR12:  High antileukemic efficiency of CD19-CAR NK cells engineered with Sleeping Beauty transposon vectors


15:00-15:15 Karl Petri, Massachusetts General Hospital, Harvard Medical School, Boston

OR13:  Global-scale CRISPR gene editor specificity profiling by ONE-seq identifies population-specific, variant off-target effects.


15:15-15:30 Lea-Isabell Schwarze University Medical Center Hamburg-Eppendorf

OR14: CCR5-edited CAR T cells for the treatment of HIV-positive cancer patients

15:30-16:00

Session 9: Ethical considerations and challenges for the future

Chairs: Toni Cathomen, University of Freiburg; Zoltan Ivics, Paul Ehrlich Institute, Langen

15:30-16:00  Tobias Cantz, Hannover Medical School   ; Thomas Heinemann, Philosophical-Theological University of Vallendar  

INV26:  Emerging bioethical challenges in gene therapy approaches 


16:00

Closing, Prizes & Awards

Chair: Hildegard Büning, Hannover Medical School